RTP Mobile Logo
Atlas of Molecular Oncology: Clinical and Translational Advances in the Management of Triple-Negative Breast Cancer
Released December 2010

Featuring five individual slide presentations from Professor Alan Ashworth, FRS and Drs Kimberly L Blackwell, Eric P Winer, Lisa A Carey and Edith A Perez. (Slide Content)

CE Disclosures and Faculty Information

  • CME credit is no longer available for this issue

    OVERVIEW OF ACTIVITY

    Triple-negative breast cancer (TNBC) represents a more aggressive, higher-risk phenotype with an increased incidence of distant recurrence and death compared to other types of breast cancer. Despite an overall increase in knowledge of the biologic and natural history of TNBC, inadequate effective therapies for this patient subset persist.

    This unique educational activity will combine the powers of art and science to communicate current management strategies and emerging therapeutic options for TNBC. The Atlas of Molecular Oncology: Clinical and Translational Advances in the Management of Triple-Negative Breast Cancer will provide clinicians with a concise, easy-to-understand slide resource to facilitate knowledge and application of optimal therapeutic approaches.

    TARGET AUDIENCE

    This activity is intended for medical, surgical and radiation oncologists and other healthcare providers involved in the treatment of breast cancer.

    LEARNING OBJECTIVES

    • Appropriately integrate molecular and genetic testing to identify patients with triple-negative, basal-like and/or BRCA-mutated breast cancer.
    • Communicate the prognostic implications of the triple-negative phenotype and its effect on established treatment selection.
    • Recognize the pathologic commonalities between triple-negative and BRCA1/2-mutated breast cancer that confer selective sensitivity to therapeutic inhibition of PARP1.
    • Explain the concept of synthetic lethality as it relates to the activity of PARP inhibitors in breast cancer.
    • Describe the relative chemosensitivity of TNBC, and identify opportunities to maximize cytotoxic effects.
    • Counsel appropriately selected patients about availability of and participation in ongoing clinical research studies focusing on the management of early and advanced TNBC.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains slides. To receive credit, the participant should review the CME information, review the slide presentations and complete the Post-test and Educational Assessment and Credit Form located on our website at CME.ResearchToPractice.com.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDrs Carey and Winer had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Prof AshworthConsulting Agreements: GlaxoSmithKline, Pfizer Inc; Patent: AstraZeneca Pharmaceuticals LP. Dr BlackwellConsulting Agreements and Speakers Bureau: GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Paid Research: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline. Dr PerezPaid Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, GlaxoSmithKline, Roche Laboratories Inc, Sanofi-Aventis.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Myriad Genetics Inc and Sanofi-Aventis.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2010
    Expiration date: December 2011

    CME credit is no longer available for this issue

Acknowledge and close

View slides: